story of the week
Venetoclax Plus Daunorubicin and Cytarabine Chemotherapy as First-Line Treatment for Adults With AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial
Lancet Haematol 2022 May 02;[EPub Ahead of Print], H Wang, L Mao, M Yang, P Qian, H Lu, H Tong, W Xie, Zhou, X Huang, Y Wang, G Xu, Y Lu, J Wei, W Mai, X Ye, H Meng, Y Shen, J Huang, W Yu, J Sun, J Sheng, X Yan, J Jin, HH ZhuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.